3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Carcinoma, Renal Cell
3
Recurrence
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Cholangiocarcinoma
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Metastatic Urothelial Cancer
1
Interventions
cemiplimab
2
zimberelimab
1
quemliclustat
1
pembrolizumab
1
lorlatinib
1
fludarabine
1
Interleukin-2
1
Docetaxel
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Non-Small Cell Lung Cancer
×
zimberelimab
×
1 year
×
Clear all
NCT05676931
2026-06-01
EDGE-Lung
Gilead Sciences
Phase 2
Active not recruiting
400 enrolled